GlassScriptPhysician profile
Katie Monterroso
NPI 1093593519
$1,503.17
in general payments reported to CMS, 2019-2025
8 companies · $640 in 2025
The $640 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $241 · 2024: $622 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.57 | 2023-2025 | Airsupra, Breztri |
| Janssen Biotech, INC. | $270.92 | 2025 | Rybrevant, Erleada |
| Novo Nordisk INC | $258.10 | 2025 | Ozempic, Wegovy, Rybelsus |
| Genmab U.S., INC. | $244.17 | 2023-2024 | Tivdak |
| E.R. Squibb & Sons, L.L.C. | $147.50 | 2024-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Jemperli |
| Eisai INC. | $122.71 | 2024 | |
| Daiichi Sankyo INC. | $29.20 | 2025 | Datroway |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Monterroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.